Trials / Completed
CompletedNCT00195299
Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck
An Exploratory Biomarker Trail of Temsirolimus in Subjects With Newly Diagnosed Advanced Stage Squamous Cell Carcinoma of the Head & Neck
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, exploratory, biomarker study of intravenous temsirolimus given once weekly for 3 weeks to newly diagnosed, advanced stage head and neck cancer subjects prior to beginning their standard therapy for their specific disease. The primary objective of this study is to identify biomarkers of temsirolimus activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Temsirolimus |
Timeline
- Start date
- 2005-04-01
- Completion
- 2007-02-01
- First posted
- 2005-09-19
- Last updated
- 2007-12-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00195299. Inclusion in this directory is not an endorsement.